The ETS transcription factors are a large family implicated in the control of cellular proliferation and tumorigenesis. In addition, chromosomal translocations involving ETS family members are associated with a range of dierent human cancers. Given the extensive involvement of ETS factors in tumorigenesis, it becomes important to identify any additional ETS genes that may also play oncogenic roles. We identify a novel gene, ELF5, that appears to belong to the ELF (E74-likefactor) subfamily of the ETS transcription factor family, based upon similarity within the`ETS domain'. ELF5 displays a similar, but more restricted, expression pattern to that of the newly isolated epithelium-speci®c ETS gene, ELF3. Unlike most other ETS family members, ELF5 is not expressed in hematopoietic compartments, but is restricted to organs such as lung, stomach, kidney, prostate, bladder and mammary gland. ELF5 is localized to human chromosome 11p13 ± 15, a region that frequently undergoes loss of heterozygosity (LOH) in several types of carcinoma, including those of breast, kidney and prostate. We ®nd that ELF5 expression is not detectable in a number of carcinoma cell lines, some of which display loss or rearrangement of an ELF5 allele. Similar to other ETS family members, ELF5 displays speci®c binding to DNA sequences containing a GGAA-core. In addition, ELF5 is able to transactivate through these ETS sequences, present upstream from a minimal promoter. Our data suggest that ELF5 may play roles in mammary, lung, prostate and/or kidney function, and possibly also in tumorigenesis.
Introduction
The ETS family of transcription factors share a highly conserved DNA binding domain, termed the`ETS domain', ®rst identi®ed in the gag-myb-ets fusion protein of avian leukemia virus E26 (Nunn et al., 1983; Watson et al., 1988; Karim et al., 1990; Gutman and Wasylyk, 1991; Seth et al., 1992) . The ETS domain recognizes and binds to purine rich GGA(A/T) core motifs in the promoters and enhancers of various target genes (Macleod et al., 1992; Wasylyk et al., 1993; Janknecht and Nordheim, 1993; Werner et al., 1995; Kodandapani et al., 1996) . The ETS family does not maintain overall similarity outside of the ETS domain, but can be grouped into subfamilies based upon variation within the ETS domain, and also by the arrangement and presence of other domains, such as those involved in transactivation and sites of phosphorylation (Lautenberger et al, 1992; Wasylyk et al., 1993; Janknecht and Nordheim, 1993) . Over 30 ETS gene family members have been identi®ed in species ranging from sea urchin to human.
Many ETS factors have been implicated in the control of cellular proliferation and tumorigenesis (Seth et al., 1992; Macleod et al., 1992; Wasylyk et al., 1993; Janknecht and Nordheim, 1993; Scott et al., 1994a; Muthusamy et al., 1995) . ETS1, ETS2, ERG2 and PU.1 are proto-oncogenes with mitogenic and transforming activity when overexpressed in ®broblasts (Seth et al., 1989; Seth and Papas, 1990; Hart et al., 1995; Moreau-Gachelin et al., 1996) . In addition, chromosomal translocations involving ETS family members are associated with dierent human cancers. ERG and ERGB/FLI1 are fused to the EWS gene in t(21;22) and t(11;22) translocations, respectively, in Ewing's sarcoma and other primitive neuroectodermal tumors (Sorensen et al., 1994; Ida et al., 1995) . FEV is fused to EWS in a subset of Ewing's tumors in t(2;22) translocations (Peter et al., 1997) . TEL is fused to the platelet-derived growth factor receptor beta (PDGFRb) gene in t(5;12) translocations of chronic myelomonocytic leukemia, and to the acute myeloid leukemia 1 (AML1) transcription factor gene in t(12;21) translocations of acute lymphoblastic leukemia (Golub et al., 1994 (Golub et al., , 1995 . Fusion of TEL to the receptor-associated kinase JAK2 results in early pre-B acute lymphoid leukemia in t(9;12), and in atypical chronic myelogenous leukemia in t(9;15;12) (Peeters et al., 1997) . Expression of Spi1 and Fli1 can be activated by position speci®c integration of the Friend murine leukemia virus in murine erythroleukemias (BenDavid et al., 1991) . Also, ETS1, ETS2 and ERG regulate the expression of metalloproteinase genes, such as stromelysin and collagenase (Buttice and Kurkinen, 1993; Buttice et al., 1996; Wasylyk et al., 1991) , which are important for extracellular matrix degradation concomitant with tumor vascularization (angiogenesis) and metastasis.
ETS factors also have important developmental roles. Pointed P2 and yan play critical roles in Drosophila eye development (O'Neill et al., 1994) . ETS2 is involved in skeletal/cartilage development (Sumarsono et al., 1996) . PU.1 null mutation results in hematopoietic abnormalities , and ETS1 is involved in transactivation of genes required for T cell function (Muthusamy et al., 1995; Sun et al., 1995; Thomas et al., 1995 Thomas et al., , 1997 and angiogenesis Vandenbunder et al., 1994; Wernert et al., 1992) .
The ETS factors are almost all expressed in hematopoietic lineages (Bhat et al., 1989 (Bhat et al., , 1990 Kola et al., 1993) , and indeed appear to function predominantly in these cells and their related neoplasms. However, the most common solid tumors in humans are carcinomas which arise from the transformation of epithelial cells. Transformed breast epithelial cells, for example, have been shown to express ETS family members GABPa, PEA3, ELF1, ETS1 and ELK1 (Scott et al., 1994b; DelannoyCourdent et al., 1996) , but expression of these ETS family members is not restricted to epithelial cells. One ETS family member, ELF3/ESX/ESE-1/ERT, has recently emerged with epithelial and epithelial-cancer speci®c expression Chang et al., 1997; Choi et al., 1998; Oettgen et al., 1997) . Given the extensive involvement of ETS factors in tumorigenesis, it becomes important to identify any additional ETS genes that may also play oncogenic roles, especially those that may be involved in epithelially derived cancers.
Here we report the cloning and initial characterization of a novel ETS family member, ELF5, that displays a similar, but more restricted, expression pattern to that of ELF3. In a comparison of ETS domains, ELF5 displays strongest similarity to the ELF/E74 subfamily of ETS factors, and is most closely related to ELF3. Other than a conserved pointed domain, however, ELF5 has little similarity to ETS family members outside of the ETS domain. ELF5 functions as a transcription factor with similar sequence-speci®c DNA binding characteristics to other ETS family members.
Results

Isolation of mouse and human ELF5 cDNAs
The murine Elf5 cDNA was isolated from an adult mouse lung cDNA library following screening with a cDNA probe containing the ETS domain of human ELF3. Amalgamation of sequence data revealed a 1437 bp sequence with a maximum open reading frame (ORF) of 759 bp, predicted to encode a 253 amino acid protein of approximately 31 kD (Figure 1a ). An upstream, in-frame stop codon suggests that this ORF represents the full-length coding sequence of ELF5. No evidence was found for alternative splicing within the ORF. Additional 91 bp of 5', and 696 bp of 3' sequences were obtained by reverse transcriptase polymerase chain reaction (PCR) and rapid amplification of cDNA ends (RACE), using day 14 mouse placental RNA. Sequence analysis revealed two discrete polyadenylation signals present in the 3' untranslated region (UTR). The ®rst of these (at 1391 bp) appears to be an overlapping poly(A) + recognition signal, AATTAA and ATTAAAA, similar to that identi®ed in the gene for C4b-binding protein by Kristensen et al. (1987) . The second is a consensus polyadenylation signal, AATAAA, at 2181 bp. These polyadenylation signals are found close to the 3' termination of the original clone and the 3' RACE product, respectively, suggesting that these represent polyA signals for two separate mRNA products. Thus, the two predicted Elf5 cDNAs are 2224 bp and 1528 bp long. Northern blot analysis, using the Elf5 coding sequence as a probe, con®rmed the presence of two predominant Elf5 transcripts in placental tissue, Elf5-a and Elf5-b, of approximately 2.5 kb and 1.5 kb respectively. Only Elf5-a was identi®ed using a 3' UTR fragment from between the polyadenylation signals as a probe (Figure 1b) , indicating that the transcripts dier in 3' UTR sequences. Interestingly, the sequence found in Elf5-a, but not Elf5-b, contains multiple ATTTA motifs that are associated with rapid mRNA turnover (Savant-Bhonsale and Cleveland, 1992; Akashi et al., 1994) .
A human ELF5 cDNA fragment was isolated from a human lung cDNA library following screening with a cDNA probe containing the coding sequence of mouse Elf5. The full coding sequence of human ELF5 was then obtained by reverse transcriptase PCR and RACE using human placental RNA. Unlike the mouse, no evidence was found for the utilization of multiple polyA + signals in human ELF5, which is supported by the observation of a single transcript in Northern analysis of human tissues (see Figure 5a ). Analysis revealed that the ELF5 sequence is predicted to encode a 255 residue amino acid protein.
Comparison of human and mouse ELF5 amino acid sequences
The predicted amino acid sequences of human and mouse ELF5 are highly conserved, with approximately 95% identity (Figure 2a) . Only a single amino acid substitution was observed within the putative ETS domain of human and mouse ELF5, and most of the other diering amino acid residues in the full-length sequences are conservative substitutions (8/13), suggesting that the two proteins are homologs (i.e. having an inferred common ancestry). Interestingly, human ELF5 does, however, contain an additional two amino acid insertion compared to mouse Elf5. In addition to the ETS domain, other features appear to be conserved between these two sequences. These include a putativè pointed' domain (Seth et al., 1992; Lautenberger et al., 1992) and several consensus casein kinase II (CKII) (Pinna, 1990) , protein kinase C (PKC) (Kishimoto et al., 1985; Woodget et al., 1986) and tyrosine kinase (Patschinsky et al., 1982; Hunter, 1982; Cooper et al., 1984) phosphorylation sites. The ETS and pointed domains are discussed below, with reference to other ETS family members, but the signi®cance of consensus phosphorylation sites in ELF5 have not yet been determined.
The ETS domain found within all members of the ETS family is responsible for sequence-speci®c DNA binding (Seth et al., 1992; Lautenberger et al., 1992; Wasylyk et al., 1993) . The putative ETS domain of human/mouse ELF5, situated at the carboxyl terminal of the protein, is highly similar to that of human/ mouse ELF3, with amino acid identity being 67%. However, this domain is only moderately similar to that of other ETS family members, with the highest amino acid identity being 49% to human NERF, 48% to Drosophila ETS4 and E74A, and 46% to human ELF1 and ELK1 (Figure 2b ). Sequence identity to other family members is in the range of 44 ± 36%. However, amino acids highly conserved amongst ETS family members (Janknecht and Nordheim, 1993) are well conserved in ELF5 (23/38). Some of these highly conserved residues, such as the three tryptophan residues in the carboxyl half of the ETS domain, have been demonstrated to be structurally critical for DNA binding of other ETS family members (Wang et al., 1992; Wasylyk et al., 1992) .
Based on ETS domain similarities, a recent phylogenetic analysis (Graves and Petersen, 1998) has proposed the grouping of ETS factors into subfamilies, one of which is the ELF (E74-like-factor) subfamily. The ELF subfamily includes Drosophila E74A, human ELF1 and NERF. We generated a phylogenetic tree, including ELF5 and recently isolated ELF3, by maximum likelihood analysis of the ETS domain ( Figure 2c ). It shows that the human and mouse ELF5 sequences group most closely with the human and mouse ELF3 sequences, and that both ELF3 and ELF5 are most closely related to Drosophila ETS4, E74A and human ELF1 and NERF within the ETS family. Thus, Drosophila ETS4, and human/mouse ELF3 and ELF5 may also fall into the ELF subfamily of ETS factors. It is for this reason that ELF5 is so named. The phylogenetic relationship of the mELF3, dETS4, hELF1, hNERF, dE74A, hTEL, dYAN, hERM, mER81, mPEA3, hELK1, mERP and hSAP1 sequences is identical to that published recently whereas the phylogenetic relationship among the remaining 12 sequences (ELF5 excluded) is dierent. These dierences occur at the basal bipartitions in the data, probably due to the use of a more rigorous phylogenetic method than that used previously. The same phylogenetic relationship among the ETS domains in dYAN, hTEL, dE74A, hELF1, hNERF and dETS4 was reported by Graves and Petersen (1998) , who obtained a majorityrule consensus of 1000 neighbor-joining trees generated by bootstrap analysis. The phylogeny in Figure 2c shows the unrooted relationship among 28 ETS domains. Any attempt to infer its root would lead to the conclusion that there has been substantial variation in the substitution rate. Because variation in this rate may aect the chances of recovering the true phylogenetic tree (Hillis et al., 1994) , we remain cautious about the phylogeny as a whole. However, if we assume that the root is somewhere near the center of the tree, we may focus on the evolution of ETS domains in dYAN, hTEL, dE74A, hELF1, hNERF, dETS4, hELF3, mELF3, hELF5 and mELF5. Given that these ETS domains occur in three taxa, we can infer at least four gene duplications (A, B, C and D in Figure 2c ). The ®rst two gene duplications (A and B) involves both protostome and deuterostome taxa (Drosophila and mammals, respectively) and therefore must have occurred before the origin of the deuterostome lineage 550 ± 750 Myr ago (Doolittle et al., 1996) . A third gene duplication (C) involves two mammalian lineages (Rodenta and Primata) and therefore must have occurred 115 ± 129 Myr ago (Easteal and Herbert, 1997) . A fourth gene duplication (D) involves human sequences only and therefore we can not infer its age. Consequently, we conclude that hELF5 and mELF5
(like hELF3 and mELF3) are orthologous gene products (i.e. their origin can be traced back to a speciation event) and that ELF3 and ELF5 are paralogous gene products (i.e. their origin can be traced back to a gene duplication) (for more details on orthology and paralogy, see Moritz and Hillis, 1996) .
The large degree of sequence divergence among ETS domains ( Figure 2b ) is paralled by considerable amounts of sequences variation outside of this domain. For instance, similarity between the non-ETS domain ELF5 and ELF3 sequences is very low, with PEST , serine rich and high mobility group (HMG) , and A/T hook (Oettgen et al., 1997) domains reported in ELF3 not apparent in ELF5. However, the pointed domain present in many of the ETS family, such as pointed, TEL, yan, ETS1 and ELF3, also appears to be present in ELF5. The pointed domain present in many ETS factors displays weak similarity to helix-loop-helix domains, responsible for protein-protein interactions (Littlewood and Evan, 1994) . The hELF5 pointed domain displays 26% amino acid residue identity to that of ERG, and 23% to 19% amongst a range of other ETS family members, including hELF3, hTEL, hGABPa, hETS1, hETS2, dYAN and dPOINTEDP2 a b ELF5, a novel member of the ETS transcription factor family J Zhou et al ( Figure 2d ). Although this similarity is relatively weak, of those amino acid residues conserved between ETS family members, 28/63 are also present in ELF5. A mitogen activated protein (MAP) kinase site, present at the extreme amino end of the pointed domain of ETS1, ETS2 and pointedP2, and involved in enhancing transactivation , does not appear to be present in ELF5. The alignment was generated using CLUSTAL W (Thompson et al., 1994) with the default settings, and the result was subsequently adjusted manually. The ETS factors examined are labeled on the left and include hELF3, mELF3, hNERF, dETS4, dE74A, hELF1, hELK1, hTEL, hERM, mER81, mPEA3, mGABPa, mERP, dETS6, mPU1, hPE1, hSAP1, hSPIB, dYAN, hERG, mFLI1, dELG, dETS3, mETS1, mETS2, mER71 , where`h' denotes human,`m' mouse and`d' Drosophila. The ETS consensus sequence is a list of the amino acids most often conserved between ETS family members. Shading denotes amino acid identity with human ELF5, and the percent identity of each ETS domain is indicated on the right. (c) Phylogenetic tree of the ETS domain produced by maximum likelihood analysis. The alignment in Figure 2b was analysed using the JTT-F substitution model (Jones et al., 1992) and local bootstrap values were estimated for all internal branches, both by using PROTML in Q mode followed by a second run in R mode (Adachi and Hasegawa, 1996) . An underlying assumption of the phylogenetic analysis is that the amino acid content does not vary signi®cantly among the sequences. This assumption was not assessed because tools for doing so are still under development (LSJ, unpublished work). Therefore, the tree may be the result of both historical and compositional components. Human chromosomal mapping of ELF5
We performed human chromosomal localization of ELF5 by PCR, using gene speci®c primers and the Genebridge 4 Radiation Hybrid DNA panel (UK HGMP Resource Centre). With these primers, a single product of the expected size (234 bp) was ampli®ed from total human DNA. The PCR reactions were then performed separately for each of the individual hybrids. The ampli®cation results (data not shown) from the 93 hybrids were submitted to the Radiation Hybrid Mapping server at Whitehead Institute/MIT Center for Genome Research for analysis. The result provided by Radiation Hybrid Mapping server demonstrated that ELF5 is localized to chromosome 11. The markers most tightly linked to ELF5 are D11S3990 (6.5cR) and D11S3998 (15.9cR) (lod score43.0), and these markers are located in the region of 11p13 ± 15 (Figure 3 ). This chromosomal region frequently undergoes loss of heterozygosity (LOH) in several types of carcinoma (Baa et al., 1996; Dahiya et al., 1997; Hirose et al., 1996; Iizuka et al., 1995; Kawana et al., 1997; Lichy et al., 1998; Wilson et al., 1996) .
Expression pattern of Elf5 in mouse tissues
Poly(A) + mRNA material derived from various mouse tissues were analysed by Northern blot hybridization using the murine Elf5 cDNA as a probe. A GAPDH probe was then used to control for RNA loading.
Analysis of Elf5 expression in adult mouse tissues revealed that Elf5, like mouse ELF3 , has a restricted expression pattern. Expression of two Elf5 transcripts, Elf5-a (2.5 kb) and Elf5-b (1.5 kb), were observed in lung (Lu), kidney (Ki), stomach (St), ovary (Ov), tongue (To), bladder (Bl) , and day 2 pregnant (2 Ma) and day 10 pregnant (10 Ma) mammary glands, but no expression was observed in liver (Li), heart (He), small intestine (Sm), spleen (Sp), thymus (Th), pancreas (Pa), skeletal muscle (Sk), colon (Co) or fat (2 Fa and 10 Fa) (Figure 4a ). Fat from day 2 (2 Fa) and day 10 (10 Fa) pregnant mice was used as a control for mammary expression, since the mammary gland contains much fat tissue. A single transcript was observed in brain (arrow ± approximately 2.1 kb), but of a dierent size to either of the two Elf5 transcripts in other organs. However, its appearance was variable in repeated experiments with adult tissues (data not shown) and at dierent developmental stages (Figures 2b and c) . Pending further analysis, it appears likely that this brain speci®c transcript is derived from cross hybridization to another highly expressed ETS family member, rather than Elf5.
Some ETS members are implicated in developmental processes. Therefore it is of interest to characterize the expression pattern of Elf5 during mouse development. We examined the expression of Elf5 in the neonatal mouse ( Figure 4b ) and during embryogenesis on days 19, 17 and 16 (Figure 4c ), and observed a similar expression pattern compared to that of the adult. (a) Northern analysis of adult mouse tissues probed with murine Elf5 cDNA (top panels) and GAPDH cDNA (lower panels). Abbreviations; Li: liver; Lu: lung; Br: brain; Ki: kidney; He: heart; Sm: small intestine; Sp: spleen; Th: thymus; St: stomach; Ov: ovary; Pa: pancreas; To: tongue; Sk: skeletal muscle; Bl: bladder; 2Fa: day 2 pregnant fat; 2 Ma: day 2 pregnant mammary gland; 10 Fa: day 10 pregnant fat; 10 Ma: day 10 pregnant mammary gland; Co: colon. Arrow indicates position of brain speci®c transcript (see text). (b) Northern analysis as above, but using RNA from day 1 neonate mouse tissues. Additional abbreviation; In: intestine. Arrow indicates position of large transcript (see text). (c) Northern analysis as above, but using RNA from day 16, 17 and 19 embryonic tissues. (d) Northern analysis as above, but using RNA from day 9.5 to day 19 placental tissues as indicated However, at day 16 stage of embryogenesis low levels of Elf5 expression were detected in brain (regular sized transcripts) and small intestine, in addition to the expression pattern observed in the adult.
Placental expression of Elf5 displayed an interesting pattern during stages of embryogenesis (Figure 4d ). Both transcripts were increasingly expressed from day 9.5 to day 13 before an overall decrease observed from day 14 to day 19, although some expression was observed at day 17.
The two predominant Elf5 mRNA transcripts were observed in variable ratios in dierent tissues, suggesting that polyadenylation sites may be utilized dierentially, or the two transcripts are subject to dierential degradation. Elf5-a was expressed more strongly in neonatal and embryonic lung and kidney (Figures 4b and c) , and adult ovary (Figure 4a ), compared to Elf5-b. Conversely, Elf5-b was stronger in adult tongue (Figure 4a) , and in all developmental stages of stomach (Figures 4a, b and c) , compared to Elf5-a. However, since these two transcripts would appear to dier only in 3' UTR sequences, they are likely to produce the same translation product. In some RNA samples a further large (410 kb) transcript was variably observed. Despite the fact that the RNA samples were poly(A) + selected, these bands could represent unspliced Elf5 transcripts or genomic contamination.
Expression pattern of ELF5 in human tissues and cancer cell lines
Expression of ELF5 in adult human organs was also analysed by Northern blot of poly(A) + mRNA probed with the human ELF5 cDNA (Figure 5a) . A single transcript of approximately 2.5 kb was strongly expressed in kidney (Ki) and prostate (Pr). However, much longer exposures of blots (data not shown) demonstrated just detectable expression of ELF5 in placenta (Pl) and lung (Lu). Further, ELF5 was cloned from human lung and placenta cDNA libraries, con®rming that it is expressed in these tissues, albeit probably at very low levels. Although this expression pattern closely resembles that observed in the mouse, it is interesting that the human ELF5 gene does not appear to utilize alternative polyadenylation sites, resulting in only a single transcript.
Given the restricted expression pattern of ELF5 in tissues commonly giving rise to carcinomas, it is of interest to examine ELF5 expression in human cancers. A panel of cancer cell lines, including carcinomas of the ovary (CaOv-3), breast (BT-549, ZR-75-1, T47D), kidney (786-O), liver (SK-HEP-1), lung (A549), amnion (WISH), prostate (DU145, PC3) and endometrium (HEC-1), and melanoma (MEL28), T-cell leukemia (Jurkat) and erythroid leukemia (K562), were analysed for ELF5 expression by RNAse protection assay (Figure 5b) . A primary ®broblast cell line (CCL32SK) was also included as a sample of nontransformed cells. Of all these cell lines only T47D, a progesterone sensitive ductal breast carcinoma, was observed to express ELF5.
To evaluate the possibility that lack of ELF5 expression in carcinoma was due to genomic alterations, a panel of breast and lung carcinoma derived cell lines were analysed by Southern blot (Figure 5c ). ELF5 gene dosage was compared to that present in DNA from normal human blood (based on the 6.5 kb BglII fragment) and controlled by hybridization with a bactin cDNA probe. These results are summarized in the BT-549 (ductal breast carcinoma); 3: ZR-75-1 (breast carcinoma); 4: T47D (ductal breast carcinoma); 5: NCI-H1299 (large cell lung carcinoma); 6: NCI-H187 (small cell lung carcinoma); 7: NCI-H322 (bronchioalveolar carcinoma); 8: NCI-H358 (bronchioalveolar carcinoma); 9: NCI-H522 (lung adenocarcinoma); 10: SK-LU-l (lung adenocarcinoma); 11: NCI-H441 (bronchioalveolar carcinoma); 12: NCI-H460 (large cell lung carcinoma); 13: NCI-H661 (large cell lung carcinoma) ELF5, a novel member of the ETS transcription factor family J Zhou et al lower panel, where`2' represents a normal allele complement. No evidence was found for allelic loss or gene rearrangement in the two breast carcinoma cell lines that did not express ELF5 (BT-549 ± lane 2, ZR-75-1 ± lane 3). However, of nine lung carcinoma cell lines, evidence for loss of an ELF5 allele was observed in two (NCI-H358 ± lane 8, NCI-H441 ± lane 11). Hybridization with an ELF3 cDNA probe, which is localized to the long arm of chromosome 1 , helped to con®rm the speci®c loss of ELF5 alleles (data not shown). Two other lung carcinoma lines (SK-LU-1 ± lane 10, NCI-H661 ± lane 13) displayed hybridization with multiple fragments (shaded arrows) in addition to those observed in normal DNA (solid arrows), possibly indicating that at least one ELF5 allele has been rearranged in these lines. Con®rmation of rearrangement, rather than restriction fragment length polymorphism (RFLP), was made by additional restriction digests (data not shown). Some cell lines appeared to have ampli®cation or additional copies of the ELF5 gene. One of these, T47D (lane 4), was the only cell line demonstrated to express ELF5, and another, SK-LU-1 (lane 10), appeared to have rearranged alleles.
Sequence-speci®c binding of Elf5 to DNA sequences containing consensus ETS sites
Although ELF5 displays similarity to the consensus ETS domain, characterizing it as an ETS family member, this sequence is still quite divergent from most other ETS family members. The hallmark of ETS factors to bind DNA sites containing a GGAAcore in a sequence-speci®c manner is however shared by ELF5, demonstrating an additional functional similarity to the ETS family. A recombinant Elf5 HIS-tag protein of approximately 29 kD, expressed in E. coli and puri®ed by metal-anity chromatography (Figure 6a , lane 4), displayed strong binding to consensus ETS binding sites, as analysed by electrophoretic mobility shift assay (EMSA) ( Figure  6b ). Elf5 bound the E74 oligonucleotide (containing a GGAA-core) (lane 1), but not to the E74m1 oligonucleotide (which had been mutated to an AGAA-core) (lane 2). The ®rst G-residue of the core has been demonstrated to be a physical point of DNA contact for ETS1, and consequently essential for DNA binding (Fisher et al., 1991; Nye et al., 1992) . Thus, Elf5 displays sequence speci®c binding to a consensus ETS binding site, binding that is disrupted by a mutation known to similarly aect other ETS family members. These results were con®rmed through competition analysis. The Elf5-E74 complex (lane 3) was eciently competed by the addition of a 100-fold excess of unlabeled E74 (lane 4), but not by E74m1 (lane 5).
Elf5 also displayed sequence speci®c binding to dierent consensus ETS binding sequences, and did so with dierential anity (Figure 6b 
Mouse ELF5 acts as a transcriptional activator
In addition to DNA binding, another characteristic of most ETS factors is their ability to transactivate from binding sites in promoters and enhancers. An exception is ERF, which displays strong repressor-like activity (Sgouras et al., 1995) . It is therefore of interest to evaluate the ability of Elf5 to function as a transcriptional activator or repressor. This is especially pertinent to Elf5 given its small size (29 kD), since absence of a transactivation domain could potentially result in competitive inhibition of transactivation by other ETS family members.
A reporter construct, containing the chloramphenicol acetyl-transferase (CAT) driven by a minimal TK promoter and multiple ETS/AP1 binding sites (from the polyomavirus enhancer), was co-transfected into COS cells together with an Elf5 expression construct (Figure 7) . Analysis of CAT activities revealed that Elf5 expression resulted in an average ®vefold transactivation of the reporter. Further, this transactivation was inhibited by addition of an anti-sense Elf5 mRNA expression vector, indicating that Elf5 transactivation was due speci®cally to the product translated from the sense construct.
Discussion
The ETS transcription factors comprise a burgeoning family of proteins with similar sequence-speci®c DNA binding properties. Much of the ETS research has focused upon functions in hematopoietic cells, but very little is known about the functions of ETS factors in other cell types. We have isolated a novel gene, ELF5, that belongs to the ETS transcription factor family. Unlike most other ETS family members (Bhat et al., 1989 (Bhat et al., , 1990 Kola et al., 1993) , ELF5 is not expressed in hematopoietic compartments, but is restricted to organs such as lung, stomach, kidney, prostate, bladder and mammary gland.
Two predominant Elf5 mRNA species in the mouse (Elf5-a and Elf5-b) appear to arise from utilization of two distinct polyadenylation sites. The larger of these two transcripts, Elf5-a, incorporates multiple A/T rich signals that have been implicated in processes of increased mRNA turnover (Savant-Bhonsale and Cleveland, 1992; Akashi et al., 1994) . Perhaps these signals are responsible for the variability of Elf5-a:Elf5-b ratios in dierent tissues, particularly the relatively lower proportion of Elf5-a observed in stomach. Only a single ELF5 transcript was observed in human tissues, of approximately the same size as Elf5-a in mouse. We are currently sequencing the full-length human ELF5 cDNA to investigate whether one of the polyadenylation signals, present in mouse, has been lost. Dierences in the polyadenylation sites present in mouse and human genes has been reported for ETS2 (Watson et al, 1990 ), but it is dicult to speculate why such species dierences might exist. The cDNA ORFs predict a mouse Elf5 protein of 253 amino acids and a human ELF5 protein of 255 amino acids. These proteins are highly homologous, with a conserved ETS domain, pointed domain and multiple putative phosphorylation sites.
The ETS domain of this new ETS family member displays highest similarity to ELF3 (67%) and moderate similarity to other ETS family members. Phylogenetic analysis indicates that both ELF3 and ELF5 display closest similarity to members of the ELF sub-family (ELF1, NERF, E74), amongst ETS factors. Therefore, we propose that ELF5 and ELF3 (and Drosophila ETS4) form part of an extended ELF subfamily within the ETS family of transcription factors.
Expression of Elf5 in the adult mouse appears to be restricted to lung, kidney, stomach, ovary, tongue, bladder and mammary gland. In the developmental stages examined, this expression pattern remains Figure 7 Transactivation by Elf5. COS cells were co-transfected with CAT reporter and Elf5 expression constructs. Transcription of the CAT gene was driven by the thymidine kinase (tk) minimal promoter with ®ve copies of the polyomavirus enhancer inserted upstream (p5Xpoly). The polyomavirus enhancer contains adjacent ETS and APl binding sites. The Elf5 sense construct (pBOSElf5s) was designed to express Elf5 protein, and the Elf5 anti-s construct (pBOSElf5as) to produce anti-sense transcripts. In the absence of expression construct the equivalent amount of base vector (pEFBOS) was co-transfected. COS cells were processed for CAT assays and the results of at least four replicates are shown as the mean with standard error of the mean (s.e.m.) bars. Statistically signi®cant results are indicated by asterisks. A single asterisk indicates moderate signi®cance (0.054P40.01) and triple asterisks indicate very high significance (P50.001) ELF5, a novel member of the ETS transcription factor family J Zhou et al basically unchanged from day 16 of embryogenesis to adult. Elf5 was also found to be expressed in the placenta during embryogenesis. Expression of ELF5 in human tissues appears to be even more restricted than that for the mouse, with expression observed only in kidney and prostate (which was not examined in the mouse). Inconsistencies between the mouse and human data involve the relatively low ELF5 expression observed in human lung, ovary and placenta compared to that of mouse. We have observed that Elf5 expression in the mouse placenta varies with developmental time points, therefore perhaps explaining the variability in levels observed with the human placental data. Similarly, we can not discount the possibility that ELF5 expression varies with age, or even perhaps within dierent parts, of the lung and ovary, not present in our human analysis. We are currently investigating the cellular distribution of ELF5 by in situ analysis. Expression of ELF5 was not examined in human stomach, tongue, bladder or mammary gland.
Most ETS genes appear to be functional, or are at least expressed, during hematopoiesis (Bhat et al., 1989 (Bhat et al., , 1990 Kola et al., 1993) . However, ELF3 is an example of an epithelial-speci®c ETS gene Oettgen et al., 1997; Chang et al., 1997) . ELF5, similarly to ELF3, is not expressed in hematopoietic compartments, such as the thymus and spleen, but is expressed in organs such as lung, kidney, stomach and prostate. Several dierences between ELF3 and ELF5 expression were however observed. ELF3 is expressed strongly in small intestine, colon and liver, whereas ELF5 does not appear to be expressed in these organs at all. Conversely, ELF5 appears to be expressed, albeit weakly, in ovary, whereas ELF3 is not. Even so, ELF5 displays a strikingly similar expression pattern to that of its closest relative, ELF3, which is perhaps related to a gene duplication event. ELF3 has been demonstrated to be expressed in an epithelial-speci®c manner, both in normal and transformed breast epithelium and in lung carcinoma cell lines . We have examined ELF5 expression in a panel of human carcinomas and found expression in only one of 11, T47D a ductal carcinoma of the breast. Even given the limited expression of ELF5 amongst the epithelial-derived carcinomas examined, it appears likely that ELF5, like ELF3, is also an epithelial-speci®c transcription factor. It is interesting to note that most cell lines derived from lung, renal, prostate, ovarian and breast cancers lacked ELF5 expression, even though the organs themselves express this gene. Analysis of genomic DNA from carcinoma cell lines was not able to clarify why ELF5 expression was not observed in two of the three breast carcinoma lines, but four of nine lung carcinoma lines displayed evidence for either loss of an allele or gene rearrangement. Interestingly the rearrangements observed appear to be identical in both independently derived cell lines, suggesting a common loss of function. All lines appeared to contain at least one normal ELF5 allele, but sequence analysis may reveal smaller mutations that adversely in¯uence expression of ELF5 (the possibility of which is supported by loss of an allele and gene rearrangement found in some cases).
We have shown that recombinant mouse Elf5 protein is capable of binding to several ETS consensus oligonucleotides, containing a GGAA core motif, in a sequence-speci®c manner. In addition, Elf5 also displayed the ability to transactivate a promoter containing consensus ETS binding sites. Although these are characteristic of many other ETS factors, it is interesting that ELF5 is capable of DNA binding and transactivation even though it is only approximately half the size of most other ETS family members. The presence of a pointed domain and multiple potential phosphorylation sites also suggest that the economy of ELF5 does not sacri®ce regulatory regions, although we are yet to demonstrate that these are functional.
Interestingly, binding of Elf5 to the E74 oligonucleotide was eciently competed by an oligonucleotide containing an ETS binding site from the erbB2 promoter. This site has previously been shown to bind and be transactivated by recombinant PEA3 and ELF3 (ESX) , but ELF5 would appear to be another ETS family member that could contribute to erbB2 expression. erbB2 is expressed in the epithelial cells of organs such as the breast, intestine, kidney and ovary (Gullick et al., 1987; Kokai et al., 1987; Mori et al., 1989; Press et al., 1990) , and its overexpression is thought to play a role in human carcinoma progression (Singleton and Strickler, 1992; Tripathy and Benz, 1994) . The expression pattern of ELF5 matches closely that of erbB2, with the exception that ELF5 does not appear to be expressed in the intestine. ETS factors have also been implicated in the regulation of other genes important to epithelial cell function and/or transformation, including c-met (Gambarotta et al., 1996) , transforming growth factor-b type II receptor (TGF-b RII) (Choi et al., 1998 ), transglutaminase-3 (Lee et al., 1996 , SPRR2A (Fischer et al., 1996) and whey acidic protein (WAP) (Welte et al., 1994) , but identi®cation of the speci®c ETS factors involved has not yet been made.
Finally, we have localized ELF5 to human chromosome 11p13 ± 15, a region which undergoes loss of heterozygosity (LOH) in many types of cancer, such as ductal breast carcinoma (Lichy et al., 1998) , lung carcinoma (Iizuka et al., 1995) , rhabdoid tumor of the kidney (Hirose et al., 1996) , prostate carcinoma (Kawana et al., 1997; Dahiya et al., 1997) , gastric carcinoma (Baa et al., 1996) , and ovarian carcinoma . This region is believed to harbor several tumor suppressor genes (Baa et al., 1996; Coleman et al., 1997; Feinberg, 1996; Gao et al., 1997; Ichikawa et al., 1996; Iizuka et al., 1995; Zenklusen et al., 1995) , based upon both LOH data and the ability to inhibit the tumorigenicity in chemically induced murine squamous cell carcinomas upon introduction of human chromosome 11 (Zenklusen et al., 1995) . It is interesting to note that other ETS genes implicated in tumorigenesis are thought to be dominant oncogenes, activated by translocation, ampli®cation or viral insertion, rather than recessive tumor suppressors. Super®cially, ELF5 appears to function similarly to other ETS family members (DNA binding and transactivation), but it is intriguing that ELF5 expression appears to be lost in many cancer cell lines, a subset of which were found to have lost an allele or have rearrangement of the ELF5 gene. A preliminary examination of ELF5 expression indicates ELF5, a novel member of the ETS transcription factor family J Zhou et al that ELF5 is not detectable in a number of primary breast carcinomas, although it is strongly expressed in adjacent normal epithelium (data not shown). Thus, it may be possible for an ETS gene, such as ELF5, to have tumor suppressor properties and to be lost in certain cancers. Indeed, it appears that ETS1 may function to suppress tumorigenicity of colon cancer cells, whereas it is usually considered to be an oncogene (Suzuki et al., 1995) . Several circumstantial lines of evidence suggest that there are unidenti®ed ETS family members with tumor suppressor properties. An ETS element in the maspin promoter appears to be active in normal mammary and prostate epithelial cells, but inactive in tumor cells (Zhang et al., 1997a, b) .
Maspin is a tumor-suppressing serpin expressed in normal breast and prostate epithelium. A recent report implicating ELF3 (ERT) in the positive regulation of TGF-b RII transcription (Choi et al., 1998) notes that a poor TGF responsiveness, observed in many tumors and thought to contribute to malignant transformation, could be caused by defects in TGF receptor expression. Potentially, defects in maspin and TGF-b RII transcription could be caused by lack of the ETS factors that normally promote their expression. We are currently investigating the possibility that ELF5, involved in LOH of chromosome 11p13 ± 15 in carcinomas, regulates the transcription of tumor suppressing genes. In summary, we have isolated a novel ETS gene of the ELF sub-family which we have named ELF5. ELF5 displays high ETS domain similarity and similar expression pattern to that of the recently isolated epithelial-speci®c ETS gene, ELF3 (ESX, ESE-1, ERT). The chromosomal localization of ELF5, and limited expression and gene rearrangement in human carcinoma cell lines, make this an interesting gene for further study in the ®eld of human cancer.
Materials and methods
Isolation and characterization of full-length murine Elf5 cDNA
The murine Elf5 cDNA was isolated from an adult lung cDNA library in Lambda ZAPII (Stratagene) following screening with a cDNA probe containing the ETS domain region of human ELF3. Additional 5' sequence and 3' sequence were obtained by RT-PCR using a Marathon cDNA synthesis Kit (Clontech) and RACE (Rapid Ampli®cation of cDNA Ends) using day 14 murine placental Poly(A) + RNA. The murine Elf5-speci®c PCR products were cloned into pGEM-T vector (Promega Corp., Madison, WI, USA). All cDNA sequences were con®rmed by sequencing both strands at least once. 5'-RACE gene-speci®c primer 1: 5'-GCCAGTCTTG-GTCTCTTCAGCATC-3'; 5'-RACE nested-gene-speci®c primer 2: 5'-AGGAGATGCAGTTGGCATCAAGCT-3'; 3'-RACE gene-speci®c primer 1: 5'-AGCCAGTGTTAT-GGGTGCTG-3'; 3'-RACE nested-gene-speci®c primer 2: 5'-ACAGTCACTTGATCCACGGCCAATCC-3'.
Isolation of human ELF5 coding sequence
A human ELF5 cDNA fragment was isolated from a human lung cDNA library (GIBCO BRL) following screening with a cDNA probe containing the coding sequence of mouse Elf5. The coding sequence was then obtained by RT-PCR using a Marathon cDNA synthesis Kit (Clontech) and RACE (Rapid Ampli®cation of cDNA Ends) using human placental Poly(A) + RNA. The human ELF5-speci®c PCR products were cloned into pGEM-T vector (Promega Corp., Madison, WI, USA). All cDNA sequences were con®rmed by sequencing both strands at least once (data not shown).
STS content mapping
The following sequence speci®c primers for human ELF5 were used for PCR. Forward primer: 5'-CCTGTGACT-CATACTGGACATC-3'; Reverse primer: 5'-CTTGTG-TGCGGATGTTCTGG-3'. The PCR reactions were performed in Opti-Primer TM 106buer #3 (100 mM TrisHCl pH 8.3, 35 mM MgCl 2 , 250 mM KCl) with 1 ml of Master Mix 506buer (20 mM Tris-HCl pH 8.0, 250 nM EDTA) (Opti-Primer TM PCR Optimization Kit, Stratagene), 50 ng of template DNA, 0.2 mg of each primer, 1 ml of 10 mM dNTPs and 0.25 U of Taq DNA polymerase in a total volume of 50 ml. PCR parameters were an initial denaturation step at 948C for 1 min, followed by 30 cycles of 948C (1 min), 608C (1 min), 728C (1 min). For Genebridge 4 Radiation Hybrid DNA panel (UK HGMP Resource Centre), PCR reactions were performed separately for each of the individual hybrids. The PCR results from the 93 hybrids were submitted to the Radiation Hybrid Mapping server at Whitehead Institute/MIT Center for Genome Research (http://www.genome.wi.mit.edu/cgi bin/contig/rhmapper.pl). The STS content mapping experiment was performed in duplicate and included PCR reactions with no DNA, total human DNA and total hamster DNA as controls.
Southern and Northern blot analysis
Northern analysis of ELF5 expression in human adult organs was performed with commercially available blots containing 2 mg of Poly(A) + RNA (Clontech). For other Northern blots Poly(A) + mRNA was isolated by a modi®cation of Gonda et al. (1992) . Genomic DNA was isolated by standard techniques (Sambrook et al., 1997) . Random-primed probes using a 898 bp human ELF5 cDNA fragment and a 940 bp StyI mouse Elf5 cDNA fragment were generated and Southern/Northern hybridizations performed using standard procedures. Blots were re-probed with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or b-actin cDNAs to verify RNA/DNA loading.
RNAse protection analysis ELF5 mRNA abundance in total RNA from human cell lines was determined as described previously (Tymms, 1995) . Anti-sense RNA probes for human ELF5 and GAPDH transcribed from linearized plasmid vectors generated full-length probes of 388 bp and 216 bp, respectively. The protected products generated by hybridization and RNAse digestion are 298 bp for ELF5 and 160 bp for GAPDH.
Cell lines and culture
Monkey COS7 cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin, and maintained in a humidi®ed incubator at 5% CO 2 and 378C.
Plasmids pHis6-Elf5 expression vector was made as follows: The murine Elf5 cDNA was ampli®ed using PCR oligonucleotide primers (5'-CGGGATCCTTGGACTCCGTAACCCA-TAGC-3' and 5'-GCAGATCTCAGAGTTTCTCTTCC-ELF5, a novel member of the ETS transcription factor family J Zhou et al TGCC-3') containing a BamHI restriction site followed by 21 nucleotides of the murine Elf5 coding sequence and a BglII restriction site followed by 19 nucleotides complementary to the last 20 nucleotides of the Elf5 coding sequence. The PCR fragment was cloned into the pGEM-T vector (Promega Corp., Madison, WI, USA), the BamHISacI restriction fragment with the Elf5 coding sequence was then cloned into the BamHI-SacI sites of the pQE30 (Qiagen, Inc. Chatsworth, CA, USA) bacterial expression vector resulting in a N-terminal fusion of Elf5 protein to six histidine residues (His-Tag).
The Elf5 mammalian expression construct (pBOSElf5s) contains the full mouse Elf5 cDNA blunt cloned into the T4 polymerase blunted XbaI site of pEFBOS (Mizushima and Nagata, 1990) . Expression from pEFBOS is driven by the elongation factor-1 promoter. The Elf5 anti-sense expression construct is similar, but with reverse orientation of the Elf5 cDNA. p5Xpoly was made by cloning multimerized polyomavirus enhancer oligonucleotides into the BamHI site of pBLCAT2.
Electrophoretic mobility shift assays (EMSA)
Puri®ed recombinant Elf5 and Ets1 proteins were produced as 6XHis-tag fusions in E. coli using the QIAexpress expression system (Qiagen). Overnight cultures were diluted 1/10 in LB broth and grown for 1 h at 378C. Expression of recombinant proteins were induced by addition of 0.1 mM IPTG and culture of cells for 2 h. Cells were harvested and sonicated in lysis buer (6 M guanidine, 20 mM Tris-HCl, 50 mM NaCl, pH 8.0), and cell debris removed by centrifugation. One ml of metal Hisanity resin was incubated with supernatants for 30 min, collected, washed in wash buer (8 M urea, 20 mM TrisHCl, 50 mM NaCl, pH 8.0), and resuspended in renaturation buer (20 mM Tris-HCl, 50 mM NaCl, 3 mM dithiothreitol (DTT), pH 8.0). Proteins were eluted from the beads in renaturation buer supplemented with 100 mM imidazole. Puri®cation and integrity of recombinant proteins were con®rmed by denaturing SDS-polyacrylamide gel electrophoresis (PAGE).
DNA binding experiments with recombinant proteins were performed using EMSA, as previously described (Thomas et al., 1995 . Brie¯y, puri®ed double stranded oligonucleotides were labeled with g-32 P dATP and T4 polynucleotide kinase. Oligonucleotide probe (1 ng) was incubated for 10 min with approximately 20 ng puri®ed Elf5/Ets1 protein in DNA binding buer (1 mM EDTA, 10 mM Tris-HCl pH 8.0, 50 mM NaCl, 3 mM DTT, 1 mg/ml BSA, 500 ng/ml poly-d(I-C)d(I-C), 500 ng/ml poly dI-dC, 200 ng/ml sheared salmon sperm DNA),+100 ng unlabelled competitor oligonucleotides, in 10 ml ®nal volume. Assays were run through non-denaturing, 7% acrylamide (29 acrylamide:1 bis-acrylamide), 0.56TBE gels at 48C.
Oligonucleotide sequences (shown in double stranded conformation)
E74
5'-gatcATAACCGGAAGTAACT-3' 3'-TATTGGCCTTCATTGActag-5' E74m1 5'-gatcATAACCAGAAGTAACT-3' 3'-TATTGGTCTTCATTGActag-5' GMETS 5'-gatcCACAGAGGAAATGATT-3' 3'-GTGTCTCCTTTACTAActag-5' MSV 5'-gatcGAGAGCGGAAGCGCGC-3' 3'-CTCTCGCCTTCGCGCGctag-5' ERBB2 5'-gatcGCTTGAGGAAGTATAA-3' 3'-CGAACTCCTTCATATTctag-5'
Transfection of COS cells and chloramphenicol acetyltransferase (CAT) assays COS7 cells were transfected with 5 mg CAT reporter plasmid and 10 mg of expression constructs by electroporation. Subcon¯uent cells were trypsinized, washed and resuspended in growth medium (as above) supplemented with 20 mM HEPES, at 5610 6 cells/ml. 300 ml of cells were mixed with 20 mg DNA in 0.4 cm gap electroporation cuvettes and pulsed at 180 V and 960 mF (Biorad Gene Pulsar). Cells were re-plated into 10 cm petri dishes, harvested 48 h later. Cell lysates were assayed for protein concentration, and 2 mg was processed for CAT assays as previously described (Thomas et al., 1995) . The basal expression of p5Xpoly was arbitrarily assigned the value of 100', and other raw data was normalized to this value. Means, and standard error of the means (s.e.m) were generated from four replicates of each experiment. Data was subject to statistical analysis using unpaired two-tailed t-tests, with resultant p values less than 0.05 considered signi®cant.
